BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...to go public via an IPO on the Stock Exchange of Hong Kong underwritten by Morgan Stanley...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...partner and head of biotechnology in Perella Weinberg Partners’ healthcare practice and managing director in Morgan Stanley’s...
BioCentury | Feb 9, 2021
Finance

Sana leapfrogs Moderna for biggest pure-play biotech IPO yet: Data Byte

...at $38.20 on Monday, giving the underwriters an incentive to buy at $25. Sana’s underwriters are Morgan Stanley...
BioCentury | Feb 4, 2021
Finance

Sana puts the pieces together, prices IPO that could soon be largest ever for a biotech

...for the first time Thursday. Several more are likely to follow for Friday’s session.Sana’s underwriters are Morgan Stanley...
BioCentury | Feb 3, 2021
Finance

argenx raises $1B as it readies to challenge Soliris

...a U.S. follow-on and 1.4 million shares at €265.69 in a private placement in Europe. J.P. Morgan, Morgan Stanley...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...Inc. is likely to raise the most money.Underwriters of Adagene’s offering are Goldman Sachs Asia, Morgan Stanley...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...in 1993-2013, he was managing director, head of capital markets, derivatives and risk management at Morgan Stanley.Chinese...
BioCentury | Sep 14, 2020
Politics, Policy & Law

PhRMA rejects Trump election gambit, triggering most favored nation order

...in other developed countries. Speaking at the Morgan Stanley...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...Chinese investors (see “Grail’s Asia Incentives”; “Grail Declines Comment on Change in IPO Plans”).Grail’s underwriters are Morgan Stanley...
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...the program: ciprofloxacin, cefaclor, cefdinir, levofloxacin, moxifloxacin, linezolid, amoxicillin and clarithromycin. In an analyst note, Morgan Stanley’s...
Items per page:
1 - 10 of 1626
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...to go public via an IPO on the Stock Exchange of Hong Kong underwritten by Morgan Stanley...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

...partner and head of biotechnology in Perella Weinberg Partners’ healthcare practice and managing director in Morgan Stanley’s...
BioCentury | Feb 9, 2021
Finance

Sana leapfrogs Moderna for biggest pure-play biotech IPO yet: Data Byte

...at $38.20 on Monday, giving the underwriters an incentive to buy at $25. Sana’s underwriters are Morgan Stanley...
BioCentury | Feb 4, 2021
Finance

Sana puts the pieces together, prices IPO that could soon be largest ever for a biotech

...for the first time Thursday. Several more are likely to follow for Friday’s session.Sana’s underwriters are Morgan Stanley...
BioCentury | Feb 3, 2021
Finance

argenx raises $1B as it readies to challenge Soliris

...a U.S. follow-on and 1.4 million shares at €265.69 in a private placement in Europe. J.P. Morgan, Morgan Stanley...
BioCentury | Jan 20, 2021
Finance

IPO queue bulges further as Adagene, NexImmune are among latest to file

...Inc. is likely to raise the most money.Underwriters of Adagene’s offering are Goldman Sachs Asia, Morgan Stanley...
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...in 1993-2013, he was managing director, head of capital markets, derivatives and risk management at Morgan Stanley.Chinese...
BioCentury | Sep 14, 2020
Politics, Policy & Law

PhRMA rejects Trump election gambit, triggering most favored nation order

...in other developed countries. Speaking at the Morgan Stanley...
BioCentury | Sep 9, 2020
Finance

Dozens of investors seek liquidity as Grail files for IPO ahead of commercial launches

...Chinese investors (see “Grail’s Asia Incentives”; “Grail Declines Comment on Change in IPO Plans”).Grail’s underwriters are Morgan Stanley...
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...the program: ciprofloxacin, cefaclor, cefdinir, levofloxacin, moxifloxacin, linezolid, amoxicillin and clarithromycin. In an analyst note, Morgan Stanley’s...
Items per page:
1 - 10 of 1626